EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN UTERINE CANCER PATIENTS
Last updated: 04 Jan 2025
10.21608/alexpo.2023.191344.1553
Heparanase, TFPI, Thromboembolic events
Iglal
Shaala
Department of Clincal and chemical
iglal.shaala88@gmail.com
Akram
Deghady
Abdelmoneim
Clinical and chemical pathology department, faculty of medicine, university of Alexandria
akram.deghady@alexmed.edu.eg
Alexandria
Mohamed
Meheissen
Ahmed
Oncology and nuclear medicine deartment faculty of medicine, university of Alexandria
mohamed.meheissen@alexmed.edu.eg
Esraa
Hussien
Mohammed
Clinical and chemical pathology department, faculty of medicine, university of Alexandria
esraaahussieen@gmail.com
5
1
38639
2023-01-01
2023-02-02
2023-01-01
16
17
2682-2636
https://alexpos.journals.ekb.eg/article_283966.html
https://alexpos.journals.ekb.eg/service?article_code=283966
1
Preliminary preprint short reports of original research
1,426
Journal
ALEXMED ePosters
https://alexpos.journals.ekb.eg/
EVALUATION OF HEPARANASE PROCOAGULANT ACTIVITY AND TISSUE FACTOR PATHWAY INHIBITOR LEVEL IN UTERINE CANCER PATIENTS
Details
Type
Article
Created At
26 Dec 2024